Qualification of M30 and M65 ELISAs as surrogate biomarkers of cell death: Long term antigen stability in cancer patient plasma

Cancer Chemotherapy and Pharmacology

Volumn 60, Issue 6, 2007, Pages 921-924

  Cummings, J ^a   Ranson, M ^b   Butt, F ^a   Moore, D ^a   Dive, C ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b CHRISTIE HOSPITAL   (United Kingdom)

Author keywords

Biomarkers; Cancer patients; M30 Apoptosense; M65 ELISA; Plasma; Stability

Indexed keywords

AEG 35156; BIOLOGICAL MARKER; CYTOKERATIN 18; M30 ANTIGEN; M65 ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ARTICLE; BLOOD SAMPLING; CANCER PATIENT; CELL DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG MECHANISM; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN CELL; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DEATH; CENTRIFUGATION; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FREEZING; HUMANS; KERATIN-18; NEOPLASM PROTEINS; OLIGONUCLEOTIDES; SPECIMEN HANDLING; TIME FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 34548558675     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-007-0437-4     Document Type: Article

References (16)

1. Ueno T, Toi M, Linder S (2005) Detection of epithelial cell death in the body by cytokeratin 18 measurement. Biomed Pharmacother 59(Suppl2):S359-S362
2. Leers MP, Kolgen W, Bjorklund V et al (1999) Immunocytochemical detection and mapping of a cytokeratin 18 neo-epitope exposed during early apoptosis. J Pathol 187:567-572
3. Kramer G, Erdal H, Mertens HJ et al (2004) Differentiation between cell death modes using measurements of different soluble forms of extracellular cytokeratin 18. Cancer Res 64:1751-1756
4. Schutte B, Henfling M, Kolgen W et al (2004) Keratin 8/18 breakdown and reorganization during apoptosis. Exp Cell Res 297:11-26
5. Cummings J, Ward TH, Lacasse E et al (2005) Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 92:532-538
6. Kramer G, Schwarz S, Hagg M et al (2006) Docetaxel induces apoptosis in hormone refractory prostate carcinomas during multiple treatment cycles. Br J Cancer 94:1592-1598
7. Cummings J, Ranson M, Lacasse E et al (2006) Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAP. Br J Cancer 95:42-48
8. Ranson M, Dive C, Ward TH et al (2005) A phase I trial of AEG35156 (XIAP antisense) administered as a 7-day continuous intravenous infusion in patients with advanced tumors. Clin Cancer Res 11:9116s, C9172
9. Anker P, Lyautey J, Lederrey C et al (2001) Circulating nucleic acids in plasma or serum. Clin Chim Acta 313:143-146
10. Rydlander L, Ziegler E, Bergman T et al (1996) Molecular characterization of a tissue-polypeptide-specific-antigen epitope and its relationship to human cytokeratin 18. Eur J Biochem 241:309-314
11. Ku NO, Liao J, Omary MB (1997) Apoptosis generates stable fragments of human type I keratins. J Biol Chem 272:33197-33203
12. Aho S (2004) Plakin proteins are coordinately cleaved during apoptosis but preferentially through the action of different caspases. Exp Dermatol 13:700-707
13. Holdenrieder S, Stieber P, Bodenmuller H et al (2001) Circulating nucleosomes in serum. Ann N Y Acad Sci 945:93-102
14. Holdenrieder S, Mueller S, Stieber P (2005) Stability of nucleosomal DNA fragments in serum. Clin Chem 51:1026-1029
15. Abid Hussein MN, Nieuwland R, Hau CM et al (2005) Cell-derived microparticles contain caspase 3 in vitro and in vivo. J Thromb Haemost 3:888-896
16. Deligezer U, Erten N, Akisik EE et al (2006) Circulating fragmented nucleosomal DNA and caspase-3 mRNA in patients with lymphoma and myeloma. Exp Mol Pathol 80:72-76